Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 241

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 4
Chunk 241
---
 Nolazol were completed, and the product candidate received
applicable regulatory approval in Latin America that would allow Eurofarma to commence commercialization of Nolazol in accordance with
the EF License Agreement.

On
August 28, 2024, we agreed with Eurofarma to terminate the EF License Agreement effective September 30, 2024. Neither party has any claims
against the other in relation to the EF License Agreement and its termination. As of December 31, 2024, we recognized $2.5 million from
the EF License Agreement in the Statements of Operations and Comprehensive loss as Other income due to the termination of the EF License
Agreement.

Recent Financing
Agreements

Private Placements

On
September 28, 2023, we entered into a short term loan agreement, or the Short Term Loan Agreement, with Ronald Hafner, the Company’s
Chairman of the Board of Directors, or the Short Term Lender, providing for an unsecured loan to the Company in the aggregate amount
of CHF 500,000, or the Short Term Loan. Pursuant to the Short Term Loan Agreement, the Short Term Loan bears interest at a rate of 10%
per annum and matures on November 30, 2023. On November 15, 2023, the Company, entered into a series of short term loan agreements, or
the Bridge Loan Agreements and together with the Short Term Loan Agreement, the Loan Agreements, with certain existing shareholders of
the Company, including Ronald Hafner, the Company’s Chairman of the Board of Directors, Felix Grisard, Jürgen Bauer and Maria
Nayvalt, or the Bridge Lenders and together with the Short Term Lender, the Lenders, providing for an unsecured loan to the Company in
the aggregate amount of CHF 875,000.00 (approximately $1,000,000.00), or the Bridge Loan. Pursuant to the Bridge Loan Agreements, the
Bridge Loans bear interest at a rate of 10% per annum and mature on the earlier of June 30, 2024 or a liquidity event with a strategic
partner.

On
March 18, 2024, we entered into an addendum to the Short Term Loan Agreement with the Short Term Lender, and a series of addendums to
the Bridge Loan Agreements with the Bridge Lenders, each providing for an extension of the maturity